Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.

Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, Jiang T, Broadwater G, Hyslop T, Hall A, Laine M, Phung L, Greene GL, Martin LA, Pancholi S, Dowsett M, Detre S, Marks JR, Crawford GE, Brown M, Norris JD, Chang CY, McDonnell DP.

Cell Rep. 2019 Oct 22;29(4):889-903.e10. doi: 10.1016/j.celrep.2019.09.032.


Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry.

Woolf DK, Li SP, Detre S, Liu A, Gogbashian A, Simcock IC, Stirling J, Kosmin M, Cook GJ, Siddique M, Dowsett M, Makris A, Goh V.

Biomark Cancer. 2019 Jun 4;11:1179299X19851513. doi: 10.1177/1179299X19851513. eCollection 2019.


Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.

Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, Huang Y, Geradts J, Jiang P, Fei T, Chi D, Zang C, Liao Q, Rennhack J, Andrechek E, Li N, Detre S, Dowsett M, Jeselsohn RM, Liu XS, Brown M.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7869-7878. doi: 10.1073/pnas.1722617115. Epub 2018 Jul 9.


Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.

Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4482-E4491. doi: 10.1073/pnas.1620993114. Epub 2017 May 15.


Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.

Detre SI, Ashley S, Mohammed K, Smith IE, Powles TJ, Dowsett M.

Cancer Prev Res (Phila). 2017 Mar;10(3):171-176. doi: 10.1158/1940-6207.CAPR-16-0247-T. Epub 2017 Jan 18.


Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.

Cuzick J, Brentnall AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.

J Clin Oncol. 2017 Mar;35(7):743-750. doi: 10.1200/JCO.2016.69.8944. Epub 2016 Dec 28.


Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.

Brentnall AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M.

Breast Cancer Res Treat. 2016 Aug;158(3):591-6. doi: 10.1007/s10549-016-3885-x. Epub 2016 Jul 11.


Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.

López-Knowles E, Gao Q, Cheang MC, Morden J, Parker J, Martin LA, Pinhel I, McNeill F, Hills M, Detre S, Afentakis M, Zabaglo L, Dodson A, Skene A, Holcombe C, Robertson J, Smith I, Bliss JM, Dowsett M; POETIC trialists.

Breast Cancer Res. 2016 Apr 1;18(1):39. doi: 10.1186/s13058-016-0696-2.


Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M.

Clin Cancer Res. 2015 Jul 1;21(13):2932-40. doi: 10.1158/1078-0432.CCR-14-1428. Epub 2014 Nov 14.


Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

Sheri A, Smith IE, Johnston SR, A'Hern R, Nerurkar A, Jones RL, Hills M, Detre S, Pinder SE, Symmans WF, Dowsett M.

Ann Oncol. 2015 Jan;26(1):75-80. doi: 10.1093/annonc/mdu508. Epub 2014 Oct 30.


Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.

Woolf DK, Beresford M, Li SP, Dowsett M, Sanghera B, Wong WL, Sonoda L, Detre S, Amin V, Ah-See ML, Miles D, Makris A.

Br J Cancer. 2014 Jun 10;110(12):2847-54. doi: 10.1038/bjc.2014.207. Epub 2014 May 15.


Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, Marchio C, Lopez-Knowles E, Ghazoui Z, Habben K, Arbogast S, Johnston S, Dowsett M.

Endocr Relat Cancer. 2011 Aug 30;18(5):565-77. doi: 10.1530/ERC-10-0046. Print 2011 Oct.


Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.

Ghazoui Z, Buffa FM, Dunbier AK, Anderson H, Dexter T, Detre S, Salter J, Smith IE, Harris AL, Dowsett M.

Clin Cancer Res. 2011 May 1;17(9):3005-12. doi: 10.1158/1078-0432.CCR-10-1704. Epub 2011 Feb 15. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4915. Clin Cancer Res. 2011 May 1;17(9). doi:10.1158/1078-0432.CCR-11-1325.


Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.

Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'hern R, Nerurkar A, Osin P, Smith IE, Dowsett M.

Breast Cancer Res. 2010;12(5):R76. doi: 10.1186/bcr2719. Epub 2010 Sep 28.


Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.

Banerjee S, A'Hern R, Detre S, Littlewood-Evans AJ, Evans DB, Dowsett M, Martin LA.

Clin Cancer Res. 2010 Aug 15;16(16):4178-87. doi: 10.1158/1078-0432.CCR-10-0456. Epub 2010 Aug 3.


Comparative validation of the SP6 antibody to Ki67 in breast cancer.

Zabaglo L, Salter J, Anderson H, Quinn E, Hills M, Detre S, A'Hern R, Dowsett M.

J Clin Pathol. 2010 Sep;63(9):800-4. doi: 10.1136/jcp.2010.077578. Epub 2010 Jul 29.


Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR.

Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.


The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.

Martin LA, Head JE, Pancholi S, Salter J, Quinn E, Detre S, Kaye S, Howes A, Dowsett M, Johnston SR.

Mol Cancer Ther. 2007 Sep;6(9):2458-67.


A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M.

J Clin Oncol. 2007 Sep 1;25(25):3816-22. Epub 2007 Aug 6.


Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G; IMPACT Trialists Group.

J Natl Cancer Inst. 2007 Jan 17;99(2):167-70.


Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S, Makris A.

Breast Cancer Res. 2006;8(3):R31. Epub 2006 Jun 21.


Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A'Hern R.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1024s-1030s.


Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.

Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S113-7. Review.


Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE.

J Clin Oncol. 2005 Apr 10;23(11):2477-92. Epub 2005 Mar 14.


Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M.

J Clin Oncol. 2005 Apr 10;23(11):2469-76. Epub 2005 Mar 7.


Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G; IMPACT Trialists.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s.


Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):524S-32S. Review.


Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR.

Clin Cancer Res. 2001 Nov;7(11):3544-50.


Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.

Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Einstein Lønning P.

Clin Cancer Res. 2001 May;7(5):1230-6.


Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts.

Detre S, Salter J, Barnes DM, Riddler S, Hills M, Johnston SR, Gillett C, A'Hern R, Dowsett M.

Int J Cancer. 1999 Apr 12;81(2):309-13.


Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas.

Dowsett M, Detre S, Ormerod MG, Ellis PA, Mainwaring PN, Titley JC, Smith IE.

Cytometry. 1998 Aug 1;32(4):291-300.


Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy.

Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M.

Breast Cancer Res Treat. 1998 Mar;48(2):107-16.


Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer.

Mainwaring PN, Ellis PA, Detre S, Smith IE, Dowsett M.

J Clin Pathol. 1998 Jan;51(1):34-7.


Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.

Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, Dowsett M.

Int J Cancer. 1997 Aug 7;72(4):608-13.


An unusual artefact in the terminal deoxynucleotidyl transferase assay for apoptotic cells.

Detre S, Ormerod MG, Titley JC, Dowsett M.

Cytometry. 1997 Jul 1;28(3):264-7.


Preoperative chemotherapy induces apoptosis in early breast cancer.

Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M.

Lancet. 1997 Mar 22;349(9055):849. No abstract available.


Oestrogen formation in breast: clinical and biological importance.

Dowsett M, Detre S, Rowlands M, Grimshaw R.

J Endocrinol. 1996 Sep;150 Suppl:S59-63.


Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance.

Dowsett M, Makris A, Ellis P, Johnston SR, Salter J, Detre S, Humphries S, Saccani-Jotti G, Powles TJ, Smith IE.

Ann N Y Acad Sci. 1996 Apr 30;784:403-11. Review. No abstract available.


The control and biological importance of intratumoural aromatase in breast cancer.

Dowsett M, Lee K, Macaulay VM, Detre S, Rowlands M, Grimshaw R.

J Steroid Biochem Mol Biol. 1996 Jan;56(1-6 Spec No):145-50. Review.


An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells.

Lee K, Macaulay VM, Nicholls JE, Detre S, Ashworth A, Dowsett M.

Int J Cancer. 1995 Jul 28;62(3):297-302.


Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution.

Thorpe PE, Detre SI, Foxwell BM, Brown AN, Skilleter DN, Wilson G, Forrester JA, Stirpe F.

Eur J Biochem. 1985 Feb 15;147(1):197-206.


The use of anti-ricin antibodies to protect mice intoxicated with ricin.

Foxwell BM, Detre SI, Donovan TA, Thorpe PE.

Toxicology. 1985 Jan;34(1):79-88.


Monoclonal antibody therapy: "model" experiments with toxin-conjugated antibodies in mice and rats.

Thorpe PE, Detre SI, Mason DW, Cumber AJ, Ross WC.

Haematol Blood Transfus. 1983;28:107-11. No abstract available.


Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin.

Thorpe PE, Brown AN, Ross WC, Cumber AJ, Detre SI, Edwards DC, Davies AJ, Stirpe F.

Eur J Biochem. 1981 Jun 1;116(3):447-54.


Serum alpha1-foetoprotein levels in 153 male patients with germ cell tumours.

Grigor KM, Detre SI, Kohn J, Neville AM.

Br J Cancer. 1977 Jan;35(1):52-8.

Supplemental Content

Support Center